Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382791 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL29398487 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL30645689 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL1044856 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL29503829 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL7420121 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL29367120 | 1.00 | TLR2 (0.62) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL14996025 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL14497949 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL30802520 | 0.96 | TLR2 (0.64) | TLR2MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| EP-4509517-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-19 | — | — | EP | disclosed |
| EP-0531443-A1 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5191015-A | Solid phase synthesis on crosslinked polymer, removal of crosslinks to solubilize | MEDICAL RESEARCH COUNCIL (GB) | 1993-03-02 | — | — | US | disclosed |
| EP-0204374-B1 | TRIPEPTIDIC COMPOUNDS HAVING HYPOTENSIVE ACTIVITY | POLIFARMA S.p.A. (IT) | 1992-12-30 | — | — | EP | disclosed |
| US-5079260-A | Side effect reduction; fluorene derivatives | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-01-07 | — | — | US | disclosed |
| WO-1991018596-A1 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | WEITZBERG MOSHE (US) | 1991-12-12 | — | — | WO | disclosed |
| US-5051404-A | Tripeptides of pyroglutamic acid, proline, tryptophan, phenylalanine or tyrosine and a natural aminoacid | ENIRICERCHE, S.P.A. (IT) | 1991-09-24 | — | — | US | disclosed |
| EP-0394318-A1 | POLYMERS AND POLYMER-PEPTIDE CONJUGATES | MEDICAL RESEARCH COUNCIL (GB) | 1990-10-31 | — | — | EP | disclosed |
| EP-0205209-B1 | DECAPEPTIDES HAVING HYPOTENSIVE ACTION AND PROCESS FOR THEIR PREPARATION | ENIRICERCHE S.p.A. (IT) | 1989-11-29 | — | — | EP | disclosed |
| WO-1989005305-A1 | POLYMERS AND POLYMER-PEPTIDE CONJUGATES | 3I RESEARCH EXPLOITATION LIMITED (GB) | 1989-06-15 | — | — | WO | disclosed |
| US-4810779-A | Decapeptides having hypotensive action and process for their preparation | ENICHEM ELASTOMERI S.P.A. (IT) | 1989-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | TLR2 2904/4885MDM2 1513/4885MDM4 2629/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | TLR2 4706/4885MDM2 30/4885MDM4 455/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | TLR2 4706/4885MDM2 30/4885MDM4 455/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | TLR2 3821/4885MDM2 164/4885MDM4 441/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | TLR2 3196/4885MDM2 85/4885MDM4 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.